• Trending
  • Latest
    Sign in Sign up
    • Log In
    • Register
    • Home
    • Discover
    • Experts
    • Home
    • Discover
    • Experts
    • Learning Lab
    • Home
    • Discover
    • Experts
    • Learning Lab
    • Mashup Score: 35
      AL amyloidosis response: a move in the “light” direction - 1 year(s) ago

      As redemonstrated by Bomsztyk et al1 in this issue of Blood, top-down mass spectrometry (MS) of blood has been transformative for diagnosing and monitoring

      Source: ashpublications.org
      Categories: General Medicine News, Partners & KOLs
      Tweet Tweets with this article
      • Profile photo of 	rajshekharucms
        rajshekharucms

        👍🏽editorial by @ADispenzieri on FLC-Mass Spect in AL amyloidosis by @awechalekar's group. I love the way Dr. Dispenzieri masterfully distills the key findings in one figure! A must-read and should be a benchmark for how to write an excellent commentary. https://t.co/oEWRnHlnOq https://t.co/Ai6Jr0BNTC https://t.co/iXGuMV4DbP

    • Mashup Score: 2
      First report of outcomes in patients with stage IIIb AL amyloidosis treated with Dara-VCD front-line therapy - PubMed - 1 year(s) ago

      Although Dara-VCD (daratumumab-bortezomib-cyclophosphamide-dexamethasone) has revolutionized the treatment of newly diagnosed Amyloid Light chain (AL) amyloidosis, patients with stage IIIb disease were excluded in the pivotal trial. We performed a multicentre retrospective cohort study to investigat …

      Source: pubmed.ncbi.nlm.nih.gov
      Categories: General Medicine News, Partners & KOLs
      Tweet Tweets with this article
      • Profile photo of 	rajshekharucms
        rajshekharucms

        Very similar to our multicenter retrospective study that showed encouraging efficacy with Dara-VCd in stage IIIb AL, with deep cardiac responses in many patients! https://t.co/TLypajQSOC https://t.co/qOtkXS3jRo

    • Mashup Score: 38
      Efficacy and safety of daratumumab plus bortezomib and dexamethasone in newly diagnosed Mayo 2004 stage IIIA or IIIB light-chain amyloidosis: a prospective phase II study - 1 year(s) ago

      Not available.

      Source: haematologica.org
      Categories: General Medicine News, Partners & KOLs
      Tweet Tweets with this article
      • Profile photo of 	rajshekharucms
        rajshekharucms

        Great to see prospective data on Dara-Vd in Stage IIIb AL #Amyloidosis! Hematologic and organ response comparable to ANDROMEDA and 2-year OS~65% (historically ~20%)! Proves that we can now successfully treat even stage IIIb! https://t.co/vvY0zqh4iR https://t.co/BR45DlmV9o https://t.co/GriqMN91Gh

    • Mashup Score: 4
      Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study - PubMed - 1 year(s) ago

      Johnson & Johnson Pharmaceutical Research and Development, and Millennium Pharmaceuticals.

      Source: pubmed.ncbi.nlm.nih.gov
      Categories: General Medicine News, Partners & KOLs
      Tweet Tweets with this article
      • Profile photo of 	rajshekharucms
        rajshekharucms

        @RahulBanerjeeMD @JanakiramMurali @HiraSMian @GKaurMD @JanssenUS @VincentRK Agree that RCT or once vs twice weekly V will never happen at this point (and I wouldn’t enroll my patient into it even if it did). However, we do have an RCT of IV vs sq Velcade, which likely led to widespread adoption of sq early on. (https://t.co/iVUzQ2ZlHW)

    • Mashup Score: 101
      Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma - 1 year(s) ago

      Click on the article title to read more.

      Source: onlinelibrary.wiley.com
      Categories: General Medicine News, Partners & KOLs
      Tweet Tweets with this article
      • Profile photo of 	rajshekharucms
        rajshekharucms

        Our paper on natural history, mode of progression, and discordance between risk-stratification models in ~100 consecutive patients with Smoldering Myeloma diagnosed since 2014 @columbiacancer (led by @Slade_Mellgard)- Now out in @Hemasphere_EHA! #mmsm 🧵 https://t.co/nz5RrtjWS6 https://t.co/VvHYMgFxRI

    • Mashup Score: 3
      Survival in smouldering myeloma and symptomatic myeloma: Is there an emerging Will Rogers phenomenon? - 1 year(s) ago

      The phenomenon of stage migration in cancers leads to apparent survival improvement in both lower and higher stages. This is due to an upward migration of patients with adverse biology from lower to higher stages, as well as newcomers in higher stages who are not as clinically advanced as the original cohort in that stage. This epidemiological paradox is called ‘Will Rogers phenomenon’ after the comedian Will Rogers, who, during the large-scale geographic migration of 1930s, had putatively said, ‘When the Okies left Oklahoma and moved to California, they raised the average intelligence level in both states’ [1].

      Source: www.ejcancer.com
      Categories: General Medicine News, Partners & KOLs
      Tweet Tweets with this article
      • Profile photo of 	rajshekharucms
        rajshekharucms

        In 2014, the diagnostic criteria of Myeloma was modified to include biomarkers (SLiM) in the absence of CRAB, leading to a potential Will Roger's phenomenon. (https://t.co/KysFrX66jt) We hypothesized that a modern cohort of pts with SMM will have a substantially lower risk of… https://t.co/JTx8BBYfhc

    • Mashup Score: 96
      Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma - 1 year(s) ago

      Click on the article title to read more.

      Source: onlinelibrary.wiley.com
      Categories: General Medicine News, Partners & KOLs
      Tweet Tweets with this article
      • Profile photo of 	rajshekharucms
        rajshekharucms

        Our paper on natural history, mode of progression, and discordance between risk-stratification models in ~100 consecutive patients with Smoldering Myeloma diagnosed since 2014 @columbiacancer (led by @Slade_Mellgard)- Now out in @Hemasphere_EHA! #mmsm 🧵 https://t.co/nz5RrtjWS6 https://t.co/VvHYMgFxRI

    • Mashup Score: 35
      ‎The Curbsiders Internal Medicine Podcast: #427 Kittleson Rules Amyloidosis on Apple Podcasts - 1 year(s) ago

      ‎Show The Curbsiders Internal Medicine Podcast, Ep #427 Kittleson Rules Amyloidosis – Feb 19, 2024

      Source: podcasts.apple.com
      Categories: General Medicine News, Partners & KOLs
      Tweet Tweets with this article
      • Profile photo of 	rajshekharucms
        rajshekharucms

        Amazing podcast episode on all things amyloidosis ⁦@thecurbsiders⁩ with ⁦@MKIttlesonMD⁩! Loved the #Kittlesonrule- “The road to bad outcomes is often paved with plausible pathophysiology, surrogate endpoints, and wishful thinking”. https://t.co/Zf8D5d36V4

    • Mashup Score: 0
      Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time - PubMed - 1 year(s) ago

      Purpose Autologous stem-cell transplantation (ASCT) has been used in patients with immunoglobulin light chain (AL) amyloidosis for more than two decades. Early experience raised concerns regarding safety with high early-mortality rates. Patients and Methods We report 20 years of experience with ASCT …

      Source: pubmed.ncbi.nlm.nih.gov
      Categories: General Medicine News, Hem/Oncs
      Tweet Tweets with this article
      • Profile photo of 	rajshekharucms
        rajshekharucms

        @Abdallah81MD @USMIRCNEWS Unfortunately, no data specifically on TRM in stage III AL in the era of Dara-VCD induction. This is the most recent data from Mayo that I am aware of [https://t.co/EuayeT6eET].

    • Mashup Score: 3
      N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression - PubMed - 1 year(s) ago

      Our group previously demonstrated that M-protein light chain (LC) glycosylation can be detected on routine MASS-FIX testing. Glycosylation is increased in patients with immunoglobulin LC amyloidosis (AL) and rarely changes over the course of a patient’s lifetime. To determine the rates of progressio …

      Source: pubmed.ncbi.nlm.nih.gov
      Categories: General Medicine News, Hematologists1
      Tweet Tweets with this article
      • Profile photo of 	rajshekharucms
        rajshekharucms

        @Amyloid_Planet @MayoClinic This is the study I am aware of that showed: "rates of progression to AL at 20 years were 21% and 3%" with vs without glycosylation respectively. https://t.co/pur5VoSZGS cc-ing @Taxkourel who may be aware of more updated data.

    Load More

    Raj Chakraborty

    @rajshekharucms

    Hematology/Oncology fellow at @ClevelandClinic. Interests: #MultipleMyeloma #Amyloidosis Opinions are my own.

    ASCO 2025

    Advertisement

    Advertisement

    MashupMD
    © 2025 - Mashup Media LLC
    • Terms of Use
    • Privacy Policy
    • Cookie Settings